Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Unknown 2Terminated 2Active not recruiting 2Suspended 1Recruiting 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Bone Neoplasms 1

Interventions

Doxorubicin 5Cyclophosphamide 4anlotinib 3Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Neoadjuvant Therapy 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1spartalizumab 1relmacabtagene autoleucel 1regorafenib 1penpulimab 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Everolimus × Sarcoma × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡